After Capital-Markets Day Flop, Novo Strikes Licensing Deal That Sends a Swedish Company's Stock Soaring

Novo Nordisk Licenses Nanexa Drug Delivery Technology

Moderately bullish activity in Pfizer with shares up 0.9%

Cboe data shows mixed options sentiment in Novo Nordisk with shares up 0.96%

Viking Therapeutics Advances VK2735 Obesity Trial, Keeping VKTX in the Weight Loss Race

Pfizer’s Japanese RSV Vaccine Study Wraps Up, Expanding Adult Market Potential

Novo Nordisk A/S Series B Stock Rises Thursday, Outperforms Market

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Pfizer call volume above normal and directionally bullish

Lilly's Next-Gen Obesity Efforts Could Tip Scales Further in Its Favor, Citi Says

Viking Therapeutics Shares Down 15% After Co Prices Upsized Stock, Convertible Offerings

U.S. Stocks on the MOVE-Everpure, Dropbox, Darden Restaurants

Viking Therapeutics, - Offering Size Increased to $275 Mln Common Stock and $225 Mln Notes

Eli Lilly Gets FDA OK for Onswik Once-Weekly Insulin Injection

Eli Lilly - Onswik Kwikpen to be Available in U.S. in 500 Units/Ml and 1,000 Units/Ml Concentrations

U.S. Food and Drug Administration (FDA) Approves Lilly's Onswik™ (Insulin Efsitora Alfa-Gobe), a Once-Weekly Basal Insulin Injection Treatment for Adults Living with Type 2 Diabetes

Novo Nordisk's new strategy hinges on something it cannot manufacture: investor confidence

Viking Therapeutics Shares Down 8.7% Premarket After Co Announces Planned Stock, Convertible Offerings

RBC Capital Remains a Hold on Pfizer (PFE)